An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Trial Profile

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Elotuzumab (Primary) ; Nivolumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Feb 2018 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.
    • 09 Feb 2018 Planned initiation date changed from 1 Sep 2017 to 1 Jul 2017.
    • 26 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top